Ainuovirine
Ainuovirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Ainuovirine inhibits HIV replication by non-competitively binding to HIV reverse transcriptase and blocking the reverse transcription process of viral RNA. Ainuovirine can be used for human immunodeficiency virus (HIV) type 1 infection.
For research use only. We do not sell to patients.
- CAS No.: 1097628-00-6
- Formula: C18H19N3O3
- Molecular Weight:325.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MT2 | EC50 |
6.1 nM
Compound: 10b
|
Antiviral activity against wild type HIV1 infected in human MT2 cells
Antiviral activity against wild type HIV1 infected in human MT2 cells
|
[PMID: 20138513] |
| MT2 | EC50 |
6.4 nM
Compound: 10b
|
Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells
Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells
|
[PMID: 20138513] |
| MT2 | EC50 |
9.6 nM
Compound: 10b
|
Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells
Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells
|
[PMID: 20138513] |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1097628-00-6
-
Molecular Weight 325.36
-
Formula C18H19N3O3
-
SMILES
N#CC1=CC(C)=CC(C(C2=C(C(C)C)C(NC(N2CC)=O)=O)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ainuovirine Related Classifications
HY-139158 Related Classifications
Powered by Bioz